Search
LENZ Therapeutics Inc
LENZAdd to Watchlist
4.290USD
+0.790+22.57%
Close 11-09 16:00（ET）
134.79MMarket Cap
LossP/E TTM
LENZ Therapeutics Inc (LENZ) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to LENZ Therapeutics Inc in the past month.
Buy
3 Strong Buy
2 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
15.000USD+391.80%
LENZ Analyst Recommendation Trends
In the current month, LENZ has received 2 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. LENZ average Analyst price target in the last month is 15.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
4
4
4
4
4
4
2
2
2
2
2
3
3
3
2
2
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
7
7
7
7
7
7
LENZ Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Apple Inc
AAPL
9
16
14
3
1
43
Ge Vernova Inc
GEV
10
21
6
1
0
38
Tapestry Inc
TPR
5
12
4
1
0
22
Verisk Analytics Inc
VRSK
5
6
9
0
0
20
FMC Corp
FMC
1
4
12
2
0
19
Avantor Inc
AVTR
1
1
15
1
0
18
Elanco Animal Health Inc
ELAN
5
9
2
0
0
16
Genuine Parts Co
GPC
2
3
8
0
0
13
Canadian Solar Inc
CSIQ
1
3
6
3
0
13
Fate Therapeutics Inc
FATE
3
3
6
0
0
12
Financial Forecasting
Based on analysts' estimates, LENZ EPS is projected to reach -0.897 in FY2026Q4, following reported EPS of -0.986 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-1.07
-1.07
-0.92
-0.90
-0.69
Actual
-1.32
-1.02
-0.99
--
--
Surprise
-23.77%
+5.34%
-7.72%
--
--
FAQs
What is LENZ Therapeutics Inc's expected revenue for the next quarter?
LENZ Therapeutics Inc's expected revenue is 4.25M.
What is LENZ Therapeutics Inc's price target?
Analysts forecast that LENZ Therapeutics Inc's price target is USD 15.00, with the highest forecast at USD 45.00 and the lowest forecast at USD 4.00.
How have LENZ Therapeutics IncLENZ's recent earnings per share performed?
The market expectation was USD -0.99, while LENZ Therapeutics IncLENZ's earnings per share (EPS) for the previous quarter was USD -1.02. EPS for the next quarter is expected at USD -0.90.
What is the analyst rating for LENZ Therapeutics Inc?
Based on the ratings of LENZ Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.